Guide to BioRAFT Research Management System

Biological Laboratories with Non-Exempt Biological Protocols

Table of Contents

Biological labs with non-exempt protocols	2
Biological Registration Wizard	3
Entering Research Projects	5
Completing Biological Surveys	10
Entering Biological Materials	12
Add Biological Registration Forms	18
Pathogen Registration	19
Viral Vector Registration Form	21
Review Biological Registration	25
Submit Registration	30
Adding Documents	33
Amendments/Editing Registrations	37

Biological labs with non-exempt protocols


Principal Investigators with a Biological lab and projects that are **not** exempt from IBC review and approval (this includes work with human and animal pathogens (risk group 2 or higher), recombinant and synthetic DNA (as defined by the NIH Guidelines) and certain biological toxins) are required to fill out the Biological survey, research project forms (protocols) and supporting forms (Pathogen and Viral Vector forms) to be reviewed and approved by the IBC committee. If you are unsure whether your work needs to be registered with the IBC visit http://ehs.utah.edu/research-safety/biosafety/institutional-biosafety-committee-ibc for further information or contact the Biosafety Office.

After completing the General Lab Registration you will need to complete the Biological registration.

- 1. Proceed by clicking on the Biological Registration Wizard Link (see page 3).
- 2. Laboratories that are required to complete a biological registration will also be required to complete the following:
 - a. The Biological registration wizard, including descriptions of projects and general biological usage survey.
 - b. The following surveys, as applicable
 - i. Human Source Materials Survey
 - ii. Laboratory Animal Cell Lines (Non-Primate) Survey
 - iii. Non-Human Primate Source Materials Survey
 - iv. Arthropods Survey
 - v. Plants Survey
 - vi. Microbial Agents Survey
 - vii. Biological Toxins Survey
 - viii. Recombinant & Synthetic Nucleic Acids Survey
 - ix. Research of Concern Survey
 - c. Additional Forms for projects involving Human and Animal Pathogens and Recombinant and Synthetic DNA
 - i. Pathogen form(s)
 - ii. Viral Vector Form(s)


Biological Registration Wizard

1. To begin your Biological Registration Wizard, click the 'Biological Registration Wizard' link.



Note if you have already completed the registration wizard (only available the first time) you will see a screen shown on page 37. Follow the instructions for editing the Biological Registration beginning on page 38

An introductory screen will appear. You have the opportunity to delegate a member of the laboratory to complete the registration. Otherwise Click "Continue."



Biological Registration Wizard

Welcome to the Biological Registration Process.

Pls are required to register their usage of biohazardous agents and materials with the Institutional Biosafety Committee (IBC).

This wizard will guide you through:

- Adding Project Forms
 A series of questions pertinent to your areas of research
 Building your "Biological Registration Summary"
 Submitting your summary to the Institutional Biosafety Committee (IBC)

Depending on your research this process will take 30 minutes to 2 hours for initial population of your profile. Survey and form data will autosave and you can return at a later time to complete and submit your registration. You will need to update your submissions or add additional forms for future re-registrations, mid-year modifications, or before new research projects begin to ensure your profile is up to date.


If you would like, you may delegate this process to another member of your lab: Delegate Now

Continue

Entering Research Projects


The first screen of the Biological Summary will appear. You will be prompted to enter some brief information about the research projects in your laboratory

A separate Project Form must be completed for each project conducted in the laboratory. Responses provided in the Project Form may require Specific Area Surveys and may trigger completion of Specific Material Entry.




Click on "Add a Project."


This will open a survey. Please complete as appropriate.



Lab Animal Tissues (N	Jon-Primate)	
Lab Animals (Non-Prin		
■ Non-Pathogenic Micro		
Pathogenic Microorga	nisms	
☐ Plants Û		
Select Agent Pathoger	nic Microorganisms	
Other Biological Source Ma	aterials:	
■ Biological Toxins		
Infectious Proteins		
Mutagenic Agents		
Recombinant or Synth	etic Nucleotides	
Select Agent Biologics	al Toxins	
✓ Viral Vectors		
Other Hazards That May Be	e Present While Working with Biological Materials:	
■ Mixed Waste ♥		
Physical Hazards		
Other Hazards		
Additional Activities:		
Shipping Biological Ma	aterials	
Dual-Use Research of Con-	cern: [Example]	
Select all that are applicable to thi	a project.	
Enhances the harmful	consequences of the agent or toxin	
	he effectiveness of an immunization against the agent or toxin without clinical and/or ag	ricultural
	or toxin resistance to clinically and/or agriculturally useful prophylactic or therapeutic inte or facilitates their ability to evade detection methodologies	rventions
	, transmissibility, or the ability to disseminate the agent or toxin	
	or tropism of the agent or toxin	
A STATE OF THE STA	tibility of a host population to the agent or toxin	
	tutes an eradicated or extinct agent or toxin." gents or toxins are any of the following: Avian influenza virus (highly pathogenic), Bacillus anthr	neie
	feria mallei, Burkholderia pseudomallei, Ebola virus, Foot-and-mouth disease virus, Francisella	
	1918 Influenza virus, Rinderpest virus, Toxin-producing strains of Clostridium botulinum, Variola	major
virus, Variola minor virus, or Ye	rsinia pestis.	
Description of Experimental	and Procedural Details: [Example]	
	and Procedural Details. [Example]	
	NATIONAL PROPERTY OF THE PROPE	
lentiviral vectors exp	pressing OCT4, SOX2, Kf14 and c-Myc	•
lentiviral vectors exp 2) Characterize differ from patients and cont	rences in cellular structure and gene expression between cells trols	
lentiviral vectors exp 2) Characterize differ from patients and cont 3) Determine if transc	rences in cellular structure and gene expression between cells	
lentiviral vectors ex; 2) Characterize differ from patients and cont 3) Determine if transc cardiomyocytes	rences in cellular structure and gene expression between cells trols duction with <u>rADV5_MYH6</u> rescues the phenotype in patient <u>iPS</u>	ż
lentiviral vectors ex 2) Characterize differ from patients and cont 3) Determine if transc cardiomyocytes	rences in cellular structure and gene expression between cells trols	
lentiviral vectors ex 2) Characterize differ from patients and cont 3) Determine if transc cardiomyocytes	rences in cellular structure and gene expression between cells trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen ab	
lentiviral vectors ex; 2) Characterize differ from patients and cont as Determine if transc cardiomyocytes Provide details that enable reviewe Include details about genetic alteral references and expand acronyms.	rences in cellular structure and gene expression between cells trols duction with <u>rADV5_MYH6</u> rescues the phenotype in patient <u>iP5</u> rs to understand the flow of the experimental investigations involving the biological materials chosen ab tions to the models used, the purpose of the alterations, any potential delaterious effects of the alterations.	
lentiviral vectors ex; 2) Characterize differ from patients and cont 3) Determine if transs cardiomyocytes Provide details that enable reviewe include details about genetic alteral references and expand acronyms. Authorizations and Permits Ag	rences in cellular structure and gene expression between cells trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abtons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project.	ns. Use
lentiviral vectors ex; 2) Characterize differ from patients and cont 3) Determine if transc cardiomyocytes Provide details that enable reviewe include details about genetic alterat references and expand acronyms. Authorizations and Permits A; Please include the applicable depending on IBC approval pi	rences in cellular structure and gene expression between cells trols duction with <u>rADV5_MYH6</u> rescues the phenotype in patient <u>iP5</u> rs to understand the flow of the experimental investigations involving the biological materials chosen ab tions to the models used, the purpose of the alterations, any potential delaterious effects of the alterations.	ns. Use
lentiviral vectors ex 2) Characterize differ from patients and cond 3) Determine if transc cardiomycoytes Provide details that enable reviewe include details about genetic alterat references and expand acronyms. Authorizations and Permits Al Please include the applicable depending on IBC approval pl. commas.	rences in cellular structure and gene expression between cells trols trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen ab tions to the models used, the purpose of the alterations, any potential deleterious effects of the alteration pplicable to this Project authorizations or permits involved with this Project. If authorization or permits are pending	ns. Use
lentiviral vectors ex; 2) Characterize differ from patients and cont 3) Determine if transc cardiomyocytes Provide details that enable reviewe include details about genetic alterat references and expand acronyms. Authorizations and Permits A; Please include the applicable depending on IBC approval pi	rences in cellular structure and gene expression between cells trols trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen ab tions to the models used, the purpose of the alterations, any potential deleterious effects of the alteration pplicable to this Project authorizations or permits involved with this Project. If authorization or permits are pending	ns. Use
lentiviral vectors ex 2) Characterize differ from patients and cond 3) Determine if transc cardiomycoytes Provide details that enable reviewe include details about genetic alterat references and expand acronyms. Authorizations and Permits Al Please include the applicable depending on IBC approval pl. commas.	rences in cellular structure and gene expression between cells trols trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen ab tions to the models used, the purpose of the alterations, any potential deleterious effects of the alteration pplicable to this Project authorizations or permits involved with this Project. If authorization or permits are pending	ns. Use
lentiviral vectors ex; 2) Characterize differ from patients and cont 3) Determine if transcardiomyocytes Provide details that enable reviewe include details about genetic alteral references and expand acronyms. Authorizations and Permits Al Please include the applicable depending on IBC approval placommas. IACUC Number:	rences in cellular structure and gene expression between cells trols trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen ab tions to the models used, the purpose of the alterations, any potential deleterious effects of the alteration pplicable to this Project authorizations or permits involved with this Project. If authorization or permits are pending	ns. Use
lentiviral vectors ex; 2) Characterize differ from patients and cont 3) Determine if transcardiomyocytes Provide details that enable reviewe include details about genetic alteral references and expand acronyms. Authorizations and Permits Al Please include the applicable depending on IBC approval placommas. IACUC Number:	rences in cellular structure and gene expression between cells trols trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen ab tions to the models used, the purpose of the alterations, any potential deleterious effects of the alteration pplicable to this Project authorizations or permits involved with this Project. If authorization or permits are pending	ns. Use
lentiviral vectors ex; 2) Characterize differ from patients and cont 3) Determine if transcardiomyocytes Provide details that enable reviewe include details about genetic alteral references and expand acronyms. Authorizations and Permits Al Please include the applicable depending on IBC approval placommas. IACUC Number:	rences in cellular structure and gene expression between cells trols trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen ab tions to the models used, the purpose of the alterations, any potential deleterious effects of the alteration pplicable to this Project authorizations or permits involved with this Project. If authorization or permits are pending	ns. Use
lentiviral vectors ex; 2) Characterize differ from patients and cont 3) Determine if transcardiomyocytes Provide details that enable reviewe include details about genetic alteral references and expand acronyms. Authorizations and Permits Al Please include the applicable depending on IBC approval placommas. IACUC Number:	rences in cellular structure and gene expression between cells trols trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen ab tions to the models used, the purpose of the alterations, any potential deleterious effects of the alteration pplicable to this Project authorizations or permits involved with this Project. If authorization or permits are pending	ns. Use
lentiviral vectors ex; 2) Characterize differ from patients and cont 3) Determine if transcardiomyocytes Provide details that enable reviewe include details about genetic alteral references and expand acronyms. Authorizations and Permits Al Please include the applicable depending on IBC approval placommas. IACUC Number:	rences in cellular structure and gene expression between cells trols trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abtons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by	ns. Use
lentiviral vectors ex; 2) Characterize differ from patients and cont 3) Determine if trans; cardiomyocytes Provide details that enable reviewe include details about genetic alterat references and expand acronyms. Authorizations and Permits A; Please include the applicable depending on IBC approval pic commas. IACUC Number: Additional Information:	rences in cellular structure and gene expression between cells trols trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen ab tions to the models used, the purpose of the alterations, any potential deleterious effects of the alteration pplicable to this Project authorizations or permits involved with this Project. If authorization or permits are pending	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols trols duction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abtons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols trols aduction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by 1000202	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols trols aduction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by 1000202	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols trols aduction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by 1000202	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols trols aduction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by 1000202	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols trols aduction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by 1000202	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols trols aduction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by 1000202	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols trols aduction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by 1000202	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols trols aduction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by 1000202	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols trols aduction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by 1000202	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols trols aduction with <u>rADVS_MYH6</u> rescues the phenotype in patient <u>iPS</u> rs to understand the flow of the experimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration policiable to this Project—authorizations or permits involved with this Project. If authorization or permits are pendit ease specify in additional information. Multiple permits of a type should be separated by 1000202	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols of the strols of the sperimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration potential information in the second potential deleterious effects of the alteration and potent	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols of the strols of the sperimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration potential information in the second potential deleterious effects of the alteration and potent	ns. Use
lentiviral vectors exi 2) Characterize differ from patients and cont 3) Determine if trans cardiomycoytes Provide details that enable reviewe include details about genetic alterat references and expand acronyms. Authorizations and Permits Ap Please include the applicable depending on IBC approval pic commas. IACUC Number: Additional Information: IRB Number: Additional Information: Allows for the collect heart defects USDA/APHIS/PPQ Permits: Additional Information:	rences in cellular structure and gene expression between cells trols of the strols of the sperimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration potential information in the second potential deleterious effects of the alteration and potent	ns. Use
lentiviral vectors extended to the control of the c	rences in cellular structure and gene expression between cells trols of the strols of the sperimental investigations involving the biological materials chosen abstrons to the models used, the purpose of the alterations, any potential deleterious effects of the alteration potential information in the second potential deleterious effects of the alteration and potent	ns. Use



Click on Submit



Repeat for all research projects on-going in your laboratory.

When complete, Click "Next Step"


Completing Biological Surveys

This will initiate a series of Surveys, dependent on the answers in the registration.

Potential Surveys that may be triggered:

- Human Source Materials Survey
- Laboratory Animal Cell Lines (Non---Primate) Survey
- Non---Human Primate Source Materials Survey
- Plants Survey
- Microbial Agents Survey
- Biological Toxins Survey
- Recombinant & Synthetic Nucleic Acids Survey
- Research of Concern Survey

Answer the questions under each tab and click "Save"




If you believe the survey does not apply, click on "Opt Out."

In this example the next step is the Recombinant or Synthetic Nucleic Acid Molecules Survey, which will confirm whether the work you are doing is exempt under the NIH guidelines. Click on each tab and answer each of the questions.

Under the second tab (Form questions), if you check yes to any of the questions your work is NOT exempt from IBC review.

Under the third tab (Exempt experiments), answer yes to any of the exemptions that apply. If you answer yes to at least one category of exemption then the work is likely exempt from IBC review. Note the expression of genes/cDNAs in a plasmid (non-viral) vector in eukaryotic cells would typically be exempt under Section III-F-8. However, if the plasmid is expressing an oncogene or biological toxin, Q8 should be answered "No."




On the last tab, click "Save"

Entering Biological Materials

Depending on the earlier responses you will be prompted to answer questions on specific biological materials, including:


- Human Cell Lines
- Human Tissues
- Plants
- Microbial Agents
 - o Bacteria, Viruses, Fungi, Parasites
- Biological Toxins
- Nucleic Acid Reagents
 - o Plasmids and Inserts
 - o Recombinant Animals

In this example the first screen asks you to enter cell lines that are used in your lab.




After adding all cell lines, click on "Next Step".

In this example we have indicated that we use human tissue (blood and cardiac tissue collected during surgery).




Click on "Next Step"

On the next screen add Microbial Agents



In this case we have added DH5-alpha bacteria which we use to propagate plasmids.

Note the viral vectors are not added here (they are not viruses). If helper viruses are used for vector propagation they would need to be added here.



Click "Next Step"

Plasmids

Add the names of plasmids commonly used in your laboratory by clicking the "Add Plasmid" button. Please note that EHS is not expecting all plasmids that are used in your lab, just the ones relevant to the registration. However, please include all plasmids that:

- 1) Can replicate in eukaryotic cells, or
- 2) Encode DNA elements that can integrate into DNA, or
- 3) Express an oncogene or biological toxin that is lethal for vertebrates at an LD50 of less than 100ng/kg body weight, or
- 4) Express genes of human pathogens (viruses, bacteria, etc).
- 5) Viral vectors


Transgenic/Recombinant Animals

Only add transgenic/recombinant animals if you are creating them in your laboratory (i.e. do not enter commercially purchased animals or generated in the University of Utah Core). However, if you are using a recombinant vector to introduce mutations/genes or knockout genes please list the animals here.

In the section entitled "Additional Details, please address the following:

Identify and describe any ecological advantages/disadvantages that transgenic animals might acquire through the proposed genetic recombination.

Describe the containment procedures that will be followed to prevent the escape of transgenic animals from the laboratory.



Click "Next Step".


Add Biological Registration Forms

Once you have completed all of the surveys and questionnaires you will be prompted to complete forms describing pathogens or recombinant viral vectors. If neither of these applies to your work click "Next Step".

- a. If you are working with human or animal pathogens you will need to register the use of these pathogenic agents. Click on the 'Add Pathogen Registration' link. Please complete a separate form for each agent.
- b. If you are working with recombinant viral vectors (e.g., lentiviral vectors, adenoviral vectors, recombinant AAV) you will need to register the use of these vectors. Click on the 'Add Viral Vector Form'. Please complete a separate form for each vector system you are proposing to use.


Note: Pathogen and viral vector forms will auto save every 75 seconds. A bar will appear at the bottom of the page to alert you when the form has been saved. You may only work on one form at a time.

c. If you have nor forms to add or are finished adding forms, click 'Next Step'. **Goto page 25 of the guide.**



Pathogen Registration

The Pathogen registration form replaces the Biological Materials Registration (BMR) currently used by the IBC. This form will auto save every 75 seconds. A bar will appear at the bottom of the page to alert you when the form has been saved.



Notes

The information provided on these forms contain the primary information required by the IBC to ensure that work practices are appropriate and provide adequate protection. The practices described in these sections should be described in detail in the PIs laboratory-specific Standard Operating Procedures (SOPs). In order to provide this information clearly to the IBC, we require one of two options:

1) The laboratory-specific SOPs can be attached to the Registration (see page 33). All questions should be answered but description can be brief or refer to the SOPs. In order to assist the PI the IBC has developed model SOPs for BSL2 and BSL2 enhanced laboratories, which can be

downloaded from the IB website (http://ehs.utah.edu/research-safety/biosafety/protocol-review/recombinant-dna-registration). **This is the preferred option for the IBC** because:

- a. It ensures that the laboratory has SOPs in place that will provide information on all aspects of safe operating procedures to personnel
- b. NIH and the Institution expect comprehensive SOPs to be available to all personnel
- c. It will be incorporated into training
- d. If the SOPs are complete, it reduces the likelihood that registrations will require prolonged IBC review
- 2. Complete descriptions of laboratory procedures can be provided on these forms. For PIs renewing IBC approved protocols much of the narrative can be copied from their current SOPs. For Step II: Project Information, in the box entitled "Provide a brief description of project(s) involving this agent', provide SOPs including, as applicable, but not limited to:
 - e. Methods of production
 - f. Methods of titering
 - g. What happens to infected cells
 - h. Decontamination procedures

However, separate "Spill Procedures" and "Post-Exposure Procedures" documents will need to be generated and added as an attachment (see page 33): templates are available on the Biosafety website (http://ehs.utah.edu/research-safety/biosafety/protocol-review/recombinant-dna-registration).


These forms cannot be cloned or copied at present. Therefore, if you need to submit multiple Pathogen Registration forms with similar narratives we recommend that you prepare the text in Word (or other word processing software) and copy into the text boxes.

NOTE: If you are using pathogens with similar properties/containment requirements/SOPs you can list multiple agents on one form, as long as all checkboxes require the same response.

Viral Vector Registration Form

The Viral Vector replaces the recombinant and synthetic nucleic acid registration forms currently used by the IBC. This form will auto save every 75 seconds. A bar will appear at the bottom of the page to alert you when the form has been saved.

Note: If you have an auto saved form, you may choose to use it or discard the form. Discarding auto save from will delete all previously saved items.



Notes

The information provided on these forms contain the primary information required by the IBC to ensure that work practices are appropriate and provide adequate protection. The practices described in these sections should be described in detail in the PIs laboratory-specific Standard Operating Procedures. In order to provide this information clearly to the IBC, we require one of two options:

- 1. The laboratory-specific SOPs can be attached to the Registration (see page 33). All questions should be answered but description can be brief or refer to the SOPs. In order to assist the PI the IBC has developed model SOPs for BSL2 and BSL2 enhanced laboratories, which can be downloaded from the IB website (http://ehs.utah.edu/research-safety/biosafety/protocol-review/recombinant-dna-registration). This is the preferred option for the IBC because:
 - a. It ensures that the laboratory has SOPs in place that will provide information on all aspects of safe operating procedures to personnel
 - b. NIH and the Institution expect comprehensive SOPs to be available to all personnel
 - c. It will be incorporated into training
 - If the SOPs are complete, it reduces the likelihood that registrations will require prolonged IBC review
- 2. Complete descriptions of laboratory procedures can be provided on these forms. For PIs renewing IBC approved protocols much of the narrative can be copied from their current SOPs.
 - In the section entitled "Describe your viral vector production methods" please include information related to viral purification and the measurement of viral titers (as applicable). In the section entitled "Provide a brief description of project(s) involving this viral system" please include (as applicable):
 - a. Descriptions of experiments using the recombinant vectors, including methods of transducing cells in culture and administration into animals
 - b. Describe methods of decontamination of potentially infected materials (cell lines, animal tissues, etc.)

However, separate "Spill Procedures" and "Post-Exposure Procedures" documents will need to be generated and added as an attachment (see page 33): templates are available on the Biosafety website (http://ehs.utah.edu/research-safety/biosafety/protocol-review/recombinant-dna-registration).

These forms cannot be cloned or copied at present. Therefore, if you need to submit multiple Viral Vector Registration forms with similar narratives we recommend that you prepare the text in Word (or other word processing software) and copy into the text boxes.

NOTE: If you are using vectors with similar properties/containment requirements/SOPs you can list multiple agents on one form, as long as all checkboxes require the same response. For example using vectors expressing different transgenes could be on a single form.

Attach vector maps (PDF format) in the documents section of the Laboratory Registration: see page 33 for instructions.

Biological Registration Forms

Your Viral Vector Registration Form has been created.

This section allows you to add registration forms for agents and activities in your laboratory. Click on each form name that applies to your laboratory.

Biological Forms Submitted

	garding	Submitted Form	Submitted By	Submission Date	<u>Last</u> <u>Updated</u>	<u>State</u>	
_	al Vector Registration Form-Adnovirus e 5 expressing Myh6	Viral Vector Registration Form	Bowles, Neil	11/10/2015 - 12:22pm	11/10/2015 - 12:22pm	In Review	<u>Edit</u>
_	al Vector Registration Form-Third neration Lentivirus System	Viral Vector Registration Form	Bowles, Neil	08/28/2015 - 9:30am	11/10/2015 - 12:17pm	Denied	<u>Edit</u>
		Delle		00/07/0045	00/00/0045		

Thank you for entering a form

Add Pathogen Registration

Register the usage of a pathogenic agent (bacteria, virus, parasite, fungus, etc). Each agent will need a separate form. *For recombinant viruses, use the Viral Vector Form.

Add Viral Vector Form

Register the usage of recombinant viruses based on the viral vector system used to produce the virus or viruses. Each viral vector system used requires a separate form. *For alteration of wild type viruses or the use of wild type viruses as vector systems, use the Pathogen Registration Form.


When finished please click "Next Step" to proceed


Previous Step


Next Step


Review Biological Registration


On the next screen you will see a summary of your Registration. If everything is correct, click "Certify" at the bottom of the screen. If there are errors they can be edited by clicking on the "edit" or "edit responses" buttons




















Once you have finished reviewing your summary, click the 'Certify' button at the bottom of the page. Go to page 30.

NOTE: If you are the delegate rather than the PI the button will say "**Notify PI**". It will state "Click below to notify the PI that changes have been made to the Live Biological Survey." Click "**Notify PI**"


You should receive the message:

- Email successfully sent to PI name, view message.
- PI name has been notified via email that the registration is ready for submission

The PI should be prompted to complete the registration as described on the next page.

Submit Registration


To certify and submit your Biological Registration to the Biosafety Officers, read the following sections and initial in each box.



Once you are ready to submit your Biological Registration, click the 'Certify and Submit' button at the bottom of the page.

Certify and Submit

The Registration is submitted to the Biosafety Program. The screen will show:



Biological Registration Wizard


- Email successfully sent to Derek Hedquist, <u>view message</u>.
 Email successfully sent to NEIL BOWLES, <u>view message</u>.
 Your biological registration has been submitted for review.

Thank you for submitting your Biological Registration! This document has been sent to your Biological Safety Officer for review. He or she may contact you for additional information or clarification. If necessary, your registration will then be passed on for review by the Institutional Biosafety Committee (IBC).

In the future, as your research changes, please return to this system and update your registration in your lab's profile. You will be notified in one year, when you will be required to review, update and recertify this information.

Continue

Click on "Continue." This will take you back to BioRAFT Dashboard.




If you do not have documents to download go to page 33.


If you need to amend your registration, go to page 37.

Adding Documents

To add documents to the Registration, click on the name of the lab in the left margin and then click on "View Lab Profile"



Click on "Documents"




Click "Attach a New Document" (bottom right) and add any documentation supporting your registration. Please submit as PDFs, if possible. Additional documents could include, for example:

Viral Vector maps


Spills and Exposure Procedures

Lab specific SOPs (if additional information or detail needs to be added to the Registration narrative). The IBC has generated model SOPs for BSL2 and BSL2 enhanced laboratories (*link to model documents*). These can be modified for BSL1 laboratories.

Select the File type. Put a check in the "Bio" box. Browse for the file and add a description. Click "Submit"



Once submitted the screen will show:



At this point your Registration is complete. If an initial review by the Biosafety Officers does not identify

Once approved by the IBC the registration will be valid for up to 3 years. Note that if the laboratory adds new viral vectors/pathogens/projects they will need to be submitted as an amendment to this Registration through BioRAFT, as described below. This will not alter the renewal date.

problems or issues they will submit it for IBC review. If the Biosafety Officers or IBC request changes to


the registration please complete the process outlined on the following page.

BioRAFT will send annual reminders for PIs to review their registration and confirm that it is still accurate.

Amendments/Editing Registrations


If you need to make an amendment to your registration either because you have made changes to the protocol (e.g. new staff/employees/students, changes in vectors/pathogens, etc) or in response to the IBC review follow the following steps;

Log in to BioRAFT.



To add or remove new personnel, click on "Manage members" and follow the instruction in the General Laboratory Guide.

To make changes to your Biological Registration, Click on "Bio Summary"




Click on "View or Update Biological Usage Summary"

This will open the Biological Usage summary page.

If there are no additional changes follow the instructions beginning on page 30. Note that if the new personnel are using viral vectors or pathogens they will need to be added to the project form as described below.


If you need to make an amendment to a form or research project, go to next page.

Editing Projects



Click on the "edit project" button to the right of the project title.


Make the necessary changes and click the "**Submit**" at the bottom of the page. This will take you back to the Biological Summary page.



If there are no additional changes follow the instructions beginning on page 30.

If you need to make an amendment to a viral vector or pathogen form, go to next page.

Editing Viral Vector or Pathogen Forms




Click on "Edit form" below the name of the agent/vector.

Make the necessary changes, clicking through the tabs.

Click on "Review and Submit" tab and click "Submit"



This will take you back to the Biological Summary page.



If there are no additional changes follow the instructions beginning on page 30.

If you need to make additional changes repeat above steps.